Press coverage about Bioverativ (NASDAQ:BIVV) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a news impact score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.1287495926478 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Bioverativ (NASDAQ:BIVV) traded up $0.25 during trading on Tuesday, reaching $53.91. The company’s stock had a trading volume of 766,700 shares, compared to its average volume of 1,622,138. Bioverativ has a 52 week low of $40.00 and a 52 week high of $64.41.
Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The company had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. The firm’s revenue was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ will post 2.45 earnings per share for the current fiscal year.
A number of analysts recently issued reports on BIVV shares. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Jefferies Group LLC reissued a “buy” rating and issued a $70.00 target price (up from $67.00) on shares of Bioverativ in a research report on Wednesday, August 9th. Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Wednesday, September 20th. Cowen and Company reissued a “buy” rating and issued a $80.00 target price on shares of Bioverativ in a research report on Friday, August 4th. Finally, Evercore ISI started coverage on Bioverativ in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $61.73.
WARNING: This article was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/11/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-bioverativ-bivv-share-price.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.